# Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

> **NCT03546842** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 201 (actual)

## Conditions studied

- Papillomavirus Infections
- Uterine Cervical Neoplasms
- Vulvar Neoplasms
- Vaginal Neoplasms
- Adenocarcinoma in Situ
- Condylomata Acuminata

## Interventions

- **BIOLOGICAL:** 9vHPV vaccine

## Key facts

- **NCT ID:** NCT03546842
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-29
- **Primary completion:** 2019-01-29
- **Final completion:** 2019-01-29
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546842, "Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03546842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*